caBozantinib in cOllectiNg ductS Renal Cell cArcInoma
This is a single-arm, phase II trial (monocentric) study designed to determine To evaluate activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria in Metastatic Collecting Duct Renal Cell Carcinoma
Collecting Duct Carcinoma (Kidney)
DRUG: cabozantinib
Objective response rate (ORR), To evaluate activity of Cabozantinib in terms of ORR according to the RECIST 1.1 criteria., 30 Month
Progression free Survival (PFS), To evaluate activity of Cabozantinib in terms of PFS, 30 Month|Overall survival (OS), To evaluate activity of Cabozantinib in terms of OS, 30 Month|Safety and Tolerability (Adverse Events), To evaluate tolerability of Cabozantinibv during the treatment in particular the Adverse Events, 30 Month
This is a single-arm, phase II trial (monocentric)